Scientists and Experts Publish on Unique EsoCap Technology for GI Tract Diseases

The team of scientists at the University of Greifswald and leading experts in the field of platform technology development for targeted drug delivery have published several papers on the unique EsoCap platform technology for the local treatment of eosinophilic esophagitis and patients with upper gastrointestinal tract diseases.


A Leap for Esophageal Health

The publications include the proof-of-concept functionality study conducted in healthy volunteers at the University of Greifswald as well as the acceptance of the EsoCap system in healthy volunteers. The EsoCap platform addresses a broad range of diseases with high unmet medical needs and unsatisfactory treatment options, including GERD, Barrett's disease and esophageal cancer.

Revolutionizing Esophageal Drug Delivery

Researchers at the University of Greifswald have developed and published a biorelevant test system for characterizing esophageal drug delivery systems. This biorelevant assay system allows characterization of the residence time of potential formulations, from small molecules to biologics, including approved and investigational agents, in the esophagus, which is fundamental to the success of local therapy.

Phase II ACESO Trial

The ACESO study design for the Phase II trial conducted by EsoCap with ESO-101 in the lead indication eosinophilic esophagitis (EoE) was presented at the EAACI (European Academy of Allergy and Clinical Immunology) Congress.
ESO-101 was tested in a multi-center, randomised, placebo-controlled, double-blind phase II trial evaluating outcomes including histological efficacy, tolerability and safety in adults with active EoE.

Paving the way for RNA drug development for oesophageal diseases

The team of scientists at the University of Greifswald have published highly promising data for the development of RNA drugs for localized use in the oesophagus, utilizing the EsoCap System. The core component is a mucoadhesive film that carries the RNA drug and is precisely applied to the oesophagus.
Research in the area of RNA has been particularly active over the last years. These new results form the basis for future research into RNA therapies for oesophageal diseases and offer a promising perspective for innovative drug formulations on the EsoCap system.


Krause, J.; Rosenbaum, C.; Grimm, M.; Rump, A.; Keßler, R.; Hosten, N.; Weitschies, W. The EsoCap-System – An Innovative Platform to Drug Targeting in the Esophagus. J. Control. Release 2020327, 1–7,

Rosenbaum, C.; Grimm, M.; Krause, J.; Rump, A.; Kessler, R.; Hosten, N.; Weitschies, W. Functionality and Acceptance of the EsoCap System—A Novel Film-Based Drug Delivery Technology: Results of an In Vivo Study. Pharmaceutics 202113, 828,

Rosenbaum, C.; Großmann, L.; Neumann, E.; Jungfleisch, P.; Türeli, E.; Weitschies, W. Development of a Hot-Melt-Extrusion-Based Spinning Process to Produce Pharmaceutical Fibers and Yarns. Pharmaceutics 202214, 1229,

Rosenbaum, C.M.; Brokmann, F.; Krause, J.; Weitschies, W. Establishment of a Dissolution Test System for the Biorelevant Characterization of Esophageal Applied Dosage Forms. J. Pharm. Sci. 2022111, 62–68,

Krause, J.; Brokmann, F.; Rosenbaum, C.; Weitschies, W. The Challenges of Drug Delivery to the Esophagus and How to Overcome Them. Expert Opin. Drug Deliv. 202219, 119–131, Please contact the corresponding author for a full text at

Brokmann, F.; Feindt, F.; Weitschies, W.; Rosenbaum, C. Development of Test Programs for the Biorelevant Characterization of Esophageal-Applied Dosage Forms. Polymers 202315, 3430,

Weide, A., Brokmann, F., Appel, B., Rosenbaum, C., Krause, J., Janke, U., Delcea, M., Weitschies, W., & Müller, S. Stability of Free and Liposomal Encapsulated RNA on a Mucoadhesive PVA Polymer for Esophageal RNA Drug Targeting Using the EsoCap System. In Advanced Therapeutics 2024. Wiley.